The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib.

Timothy J Brown Arielle Yablonovitch Jacob E Till Jennifer Yen Lesli A Kiedrowski Ryan Hood Mark H O'Hara Ursina Teitelbaum Thomas Benjamin Karasic Charles Schneider Erica L Carpenter Katherine L Nathanson Susan M Domchek Kim A Reiss

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Acquired reversion variants were uncommon but detrimental in a population of patients with advanced BRCA or PALB2 related PDAC who received maintenance rucaparib. Reversion variants led to rapid progression on PARPi, rapid failure of subsequent platinum-based treatment and poor overall survival of patients. The identification of such variants in the blood may have both predictive and prognostic value.

Keyphrases

copy number
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
peritoneal dialysis
prognostic factors
loop mediated isothermal amplification
patient reported outcomes
free survival
quantum dots
drug induced
bioinformatics analysis